2003
DOI: 10.1002/ptr.1082
|View full text |Cite
|
Sign up to set email alerts
|

Correction of haemorheological disturbances in myocardial infarction by diquertin and ascorbic acid

Abstract: In a model of the high blood viscosity syndrome, developed after myocardial infarction in rats, it was observed that a therapy of a combination of diquertin (20 mg/kg) and ascorbic acid (50 mg/kg) for a -period of 6 days, resulted in an improvement of haemorheological indices. The decrease in blood -viscosity was primarily due to an improved deformability of erythrocytes, and to some extent, due to a decrease in the content of plasma fibrinogen and erythrocyte aggregation.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2012
2012
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 9 publications
(2 citation statements)
references
References 8 publications
0
2
0
Order By: Relevance
“…Additionally, the study explored the combined effects of diquertin and ascorbic acid in vivo (in living rats) during cerebral ischemia. This combination appeared to lessen the severity of high blood viscosity syndrome, potentially contributing to improved blood flow and red blood cell function (Plotnikov et al, 2003).…”
Section: Ascorbic Acid and Diquertinmentioning
confidence: 99%
“…Additionally, the study explored the combined effects of diquertin and ascorbic acid in vivo (in living rats) during cerebral ischemia. This combination appeared to lessen the severity of high blood viscosity syndrome, potentially contributing to improved blood flow and red blood cell function (Plotnikov et al, 2003).…”
Section: Ascorbic Acid and Diquertinmentioning
confidence: 99%
“…Diquertin ® is the first pharmaceutical product based on DHQ that has been registered in Russia. It was approved as an antioxidant in the treatment of acute pneumonia, chronic obstructive pulmonary disease, asthma, coronary heart disease, and supraventricular arrhythmia ( Kolhir et al, 1998 ; Plotnikov et al, 2003 ). The reference sample of DHQ was developed to standardize the active pharmaceutical ingredient (API) of Diquertin ® .…”
Section: Introductionmentioning
confidence: 99%